Insights Into the Hepatocellular Carcinoma Patient Journey: Results of the First Global Quality of Life Survey
Open Access
- 15 March 2018
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 14 (17) , 1701-1710
Abstract
Aim: To better understand the hepatocellular carcinoma (HCC) patient journey, we conducted a patient survey across 13 countries. Methods: The survey included closed- and open-ended questions developed using an iterative process to gather information on demographics, diagnosis and treatment. Patients self-selected or were directed to the online survey by their doctor. Results: A total of 256 patients completed the survey. More than two-thirds (68%) felt they did not receive enough information about HCC at diagnosis. Treatments included oral anticancer therapy, transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT). A total of 81% receiving sorafenib, 45% receiving SIRT and 32% receiving TACE reported impaired quality-of-life (QoL). A total of 42, 19 and 0% of patients using sorafenib rated their current QoL as ‘poor’, ‘good’ and ‘excellent’, respectively; compared with SIRT (22, 33 and 6%) or TACE (11, 37 and 13%). Conclusion: Most patients with HCC require additional acces...Keywords
Funding Information
- Sirtex Medical Limited
- Pfizer Inc
- AbbVie Inc
- Gilead Sciences
- Merck Inc
- Janssen Inc
- Springbank Inc
- Intercept Inc
- Celgene Canada Inc
This publication has 22 references indexed in Scilit:
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateHepatology International, 2017
- Hepatocellular carcinoma: a reviewJournal of Hepatocellular Carcinoma, 2016
- Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinomaJournal of Hepatocellular Carcinoma, 2016
- Treatment of intermediate-stage hepatocellular carcinomaNature Reviews Clinical Oncology, 2014
- Transarterial chemoembolization and bland embolization for hepatocellular carcinomaWorld Journal of Gastroenterology, 2014
- Epidemiology of Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2013
- Hepatocellular carcinomaThe Lancet, 2012
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999